Flexsteel Industries, Inc. reported fiscal second‑quarter 2026 results that surpassed analyst expectations, with net sales of $118.25 million—up 9.0% year‑over‑year—and a gross margin of 22.7%, an increase from 21.0% in the same period a year earlier.
Revenue growth was driven primarily by higher unit volumes in sourced soft‑seating products and the ability to pass on tariff surcharges to customers. The company also benefited from a favorable sales mix that tilted toward higher‑margin items. However, lower volumes in made‑to‑order soft‑seating and the homestyles ready‑to‑assemble category partially offset the gains, keeping the overall growth modest.
Operating income rose to $9.0 million, while diluted earnings per share reached $1.18, beating the consensus estimate of $0.79 by $0.39. The earnings beat was largely attributable to disciplined cost management and a shift toward higher‑margin product mix, which helped offset the impact of increased SG&A expenses that rose to 15.1% of net sales from 14.9% a year earlier.
Management did not provide new forward guidance, citing uncertainty around demand and tariff‑related inventory costs. The company warned that margin dilution could occur in the second half of the fiscal year as tariff‑laden inventory is sold, signaling caution despite the strong current quarter.
CEO Derek Schmidt highlighted the company’s agility and disciplined execution, noting that pricing power and strategic investments in growth initiatives are sustaining profitability. CFO Michael Ressler echoed this sentiment, acknowledging expected margin pressure from tariffs but emphasizing continued focus on cost control. Analysts responded positively to the earnings beat, underscoring the company’s resilience amid uneven industry demand and ongoing tariff challenges.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.